stoxline Quote Chart Rank Option Currency Glossary
  
Organogenesis Holdings Inc. (ORGO)
3.7  0.02 (0.54%)    02-14 16:00
Open: 3.72
High: 3.78
Volume: 215,003
  
Pre. Close: 3.68
Low: 3.695
Market Cap: 465(M)
Technical analysis
2025-02-14 4:50:23 PM
Short term     
Mid term     
Targets 6-month :  4.49 1-year :  5.25
Resists First :  3.84 Second :  4.49
Pivot price 3.61
Supports First :  3.24 Second :  2.87
MAs MA(5) :  3.64 MA(20) :  3.58
MA(100) :  3.34 MA(250) :  3.01
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  62.2 D(3) :  55.7
RSI RSI(14): 57.7
52-week High :  4.57 Low :  2.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ORGO ] has closed below upper band by 31.6%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.78 - 3.79 3.79 - 3.81
Low: 3.67 - 3.68 3.68 - 3.69
Close: 3.68 - 3.7 3.7 - 3.72
Company Description

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Headline News

Fri, 31 Jan 2025
JPMorgan Chase & Co. Increases Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat

Mon, 27 Jan 2025
Organogenesis to Report Q4 and Full Year 2024 Financial Results on February 27 - StockTitan

Thu, 19 Dec 2024
3 Penny Stocks to Watch for Big Gains in 2025 - Inkl

Wed, 13 Nov 2024
Organogenesis Holdings Secures $130M Investment for Growth - TipRanks

Wed, 13 Nov 2024
Avista Healthcare Partners Invests in Organogenesis Holdings’ Series A Convertible Preferred Stock - Ropes & Gray LLP

Tue, 12 Nov 2024
Organogenesis Secures $130M Investment from Avista, Strengthens Growth Strategy - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 126 (M)
Shares Float 60 (M)
Held by Insiders 45.9 (%)
Held by Institutions 51.7 (%)
Shares Short 10,420 (K)
Shares Short P.Month 11,000 (K)
Stock Financials
EPS -0.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.09
Profit Margin -1.7 %
Operating Margin 5.4 %
Return on Assets (ttm) 1.6 %
Return on Equity (ttm) -2.7 %
Qtrly Rev. Growth 6 %
Gross Profit (p.s.) 2.72
Sales Per Share 3.61
EBITDA (p.s.) 0.22
Qtrly Earnings Growth 350 %
Operating Cash Flow 14 (M)
Levered Free Cash Flow 13 (M)
Stock Valuations
PE Ratio -74
PEG Ratio 0
Price to Book value 1.76
Price to Sales 1.02
Price to Cash Flow 33.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android